Brennan v. NCAComp Inc.

District Court, N.D. New York·Decided November 23, 2022·No. 3:22-cv-00127·Unknown

Opinion

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF NEW YORK _____________________________________________

KEVIN JOSEPH GABRIEL BRENNAN,

Plaintiff,

v.

NCACOMP INC., Owner Kevin Gregory; 3:22-CV-0127 JOLEEN M. BOLGER, (Snowdon) Manager, (GTS/ML) NCA Inc.; DR. ANNE M. CAULKINS; DR. IRA BREITE; and RENE BARNES (Picirrili),

Defendants. _____________________________________________

APPEARANCES: OF COUNSEL:

KEVIN JOSEPH GABRIEL BRENNAN Plaintiff, Pro Se 319 Exchange Avenue, Townhouse #20 Endicott, New York 13760

MIROSLAV LOVRIC, United States Magistrate Judge

ORDER and REPORT-RECOMMENDATION The Clerk has sent this pro se second amended complaint filed by Kevin Joseph Gabriel Brennan (“Plaintiff”) to the Court for review. (Dkt. No. 16.) For the reasons discussed below, I recommend that Plaintiff’s Second Amended Complaint (Dkt. No. 16) be dismissed in its entirety without leave to amend. I. BACKGROUND As set forth in the undersigned’s Order and Report-Recommendation dated April 25, 2022, Plaintiff commenced this action on February 10, 2022, by the filing of a Complaint alleging that his rights were violated by defendants NCAComp Inc., Joleen Bolger, Dr. Anne M. Caulkins, Dr. Ira Breite,1 and Rene Barnes (collectively “Defendants”). (Dkt. No. 1.) On March 25, 2022, Plaintiff filed an amended complaint as of right, which superseded his original complaint. (See Dkt. No. 5 [Am. Compl.]); Int’l Controls Corp v. Vesco, 556 F.2d 665, 668 (2d Cir. 1977) (“It is well established that an amended complaint ordinarily supersedes the original,

and renders it of no legal effect.”). After granting Plaintiff leave to proceed in forma pauperis, the undersigned conducted a review of his Amended Complaint pursuant to 28 U.S.C. § 1915, and recommended that the Court dismiss the Amended Complaint (1) with leave to replead to the extent that it asserted claims pursuant to (a) 42 U.S.C. § 1983, (b) the Americans with Disabilities Act (“ADA”), (c) New York State law for intentional infliction of emotional distress, and (d) New York State Workers’ Compensation law for the denial of a prescribed gym membership, for failure to state a claim upon which relief may be granted, and (2) without leave to replead to the extent that it asserted claims pursuant to (a) the Hippocratic Oath, and (b) New York State Workers’

Compensation Law exclusive remedy, for failure to state a claim upon which relief may be granted. (Dkt. No. 6.) On August 4, 2022, Chief United States District Judge Glenn T. Suddaby issued a decision and order that accepted and adopted the undersigned’s Order and Report- Recommendation in its entirety. (Dkt. No. 15.)

1 Plaintiff appears to include claims against Defendant Breite in the body of the Second Amended Complaint. (See generally Dkt. No. 16.) However, the caption of the Second Amended Complaint appears to replace Defendant Breite with Ascension Lourdes. (Dkt. No. 16 at 1.) On September 3, 2022, Plaintiff filed a Second Amended Complaint, which is pending before the Court for review. (Dkt. No. 16.) Plaintiff’s Second Amended Complaint is—in most respects—virtually identical to his Amended Complaint. (Compare Dkt. No. 5 at 3-14, with Dkt. No. 16 at 5-22.) In his Second Amended Complaint, Plaintiff alleges that on November 1, 1995, he

sustained an injury at work, which resulted in permanent disability. (See generally Dkt. No. 16.) Plaintiff alleges that “in the summer of 2018”2 his New York State workers’ compensation claim was sold to Defendant NCAComp Inc. and Defendant Bolger was assigned as his claim examiner manager. (Id.) Plaintiff alleges that on December 14, 2018, he was injected with Depomedrol by Defendant Caulkins while he was also taking Meloxicam and Voltaren Gel. (Id.) Plaintiff alleges that in January 2019, he “experienced the worst episode of rectal bleeding he had ever had.” (Id.) Plaintiff alleges that due to his rectal bleeding, he went to “the Lourdes Walk-in,” where he was directed to stop taking the Meloxicam but the Voltaren Gel that he was prescribed

was not discussed. (Id.) Plaintiff alleges that on February 10, 2019, he filled his prescription for Voltaren Gel, but the amount that he was usually prescribed doubled “from two tubes to four.” (Id.) Plaintiff alleges that, pursuant to New York State Workers’ Compensation Law, any prescription medication change must be accompanied by either an appointment where the change was requested or a written order from a treating physician explaining why the change was necessary.

2 Plaintiff also states in the Second Amended Complaint that his workers’ compensation claim was “turned over to” Defendant NCA Comp. in the spring of 2018. (Compare Dkt. No. 16 at 4, with Dkt. No. 16 at 7.) However, the exact season during which Defendant NCAComp began administering Plaintiff’s workers’ compensation claim is immaterial for purposes of this review. (Id.) Plaintiff alleges that he did not request a change in the amount of Voltaren Gel and he has not seen any written order explaining a need for the increase. (Id.) Plaintiff alleges that on February 26, 2019, he was examined by Dr. Saleem, who ordered a colonoscopy to determine the cause of Plaintiff’s rectal bleeding. (Id.) However, Plaintiff alleges that he did not have the colonoscopy procedure because his request through workers’

compensation was not approved and he did not have health insurance. (Id.) Plaintiff alleges that, at some point in time in 2017, due to the rectal bleeding, on his own accord, he stopped taking all of the other medication he was prescribed except the Voltaren Gel. (Id.) Plaintiff alleges that on June 1, 2019, he obtained health insurance. (Id.) Plaintiff alleges that he had his first colonoscopy on June 12, 2019, and was diagnosed with ulcerative colitis, which requires that he take Mesalamine for the rest of his life. (Id.) Plaintiff alleges that on June 12, 2019, he applied the Voltaren Gel and looked closely at the container, which contained a warning to discontinue use if rectal bleeding occurred. (Id.) Plaintiff alleges that he

immediately ceased use of Voltaren Gel and began taking Mesalimine, and the rectal bleeding stopped the following day. (Id.) Plaintiff alleges that he has sought to have his ulcerative colitis diagnosis included in his workers’ compensation claim associated with his original injury. (Id.) Plaintiff alleges that Voltaren Gel is “a powerful NSAID which contains the chemicals known to cause deterioration of the mucosal walls of the colon.” (Id.) Plaintiff alleges that in July 2018, Defendant Caulkins stated that Plaintiff’s prescription for Voltaren Gel could not be increased because of the toxicity of it. (Id.) Plaintiff alleges that he filed a medical malpractice lawsuit in New York State court against Defendant Caulkins, and that in retaliation, she improperly doubled his prescription for Voltaren Gel. (Id.) Plaintiff alleges that Defendant Bolger improperly authorized his Voltaren Gel prescription change but failed to authorize the colonoscopy procedure. (Id.) Plaintiff alleges that Defendant NCAComp and its employees intentionally deny medical

Free access — add to your briefcase to read the full text and ask questions with AI

Brennan v. NCAComp Inc., (N.D.N.Y. 2022).

Brennan v. NCAComp Inc. (Brennan v. NCAComp Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Carnegie-Mellon University v. Cohill
484 U.S. 343 (Supreme Court, 1988)
Neitzke v. Williams
490 U.S. 319 (Supreme Court, 1989)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Igarashi v. Skulls & Bones
438 F. App'x 58 (Second Circuit, 2011)